PD1 and LAG3 inhibition as second plus line treatment after EGFR antibody-containing therapy in RAS/BRAF wildtype, MMRp metastatic colorectal cancer
Volume
34
Pagination
S53 - S54
DOI
10.1016/j.annonc.2023.04.167
Journal
ANNALS OF ONCOLOGY
ISSN
0923-7534